A growing body of evidence indicates that the enzyme DNA topoisomerase II is an important target for the anti-tumor effect of a diverse group of drugs including intercalating agents and epipodophyllotoxins. The important properties common to all these agents which allow them to interact with the enzyme are unknown. Based on the fact that the known active agents are structurally diverse, possess important clinical anti-tumor activity and share a common intracellular target, we believe it is highly likely that other compounds exist which, by virtue of their interaction with topoisomerase, will exhibit useful anti-tumor activity. Thus, the goals of our program are (1) to elucidate the nature of the physical interaction of topoisomerase II with specific, active anti-tumor agents; (2) to explore the potential of DNA topoisomerase I as a therapeutic target; (3) to design new agents directed at topoisomerase I and II; (4) to develop sensitive, efficient assays for screening new compounds for activity against topoisomerases I and II and (5) to characterize topoisomerases in vivo in ways which will elucidate the biological bases for therapeutic success or failure.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Florida
Schools of Medicine
United States
Zip Code
Chen, A Y; Liu, L F (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218
Tsao, Y P; Russo, A; Nyamuswa, G et al. (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53:5908-14
Woessner, R D; Eng, W K; Hofmann, G A et al. (1992) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4:481-8
Mattern, M R; Hofmann, G A; McCabe, F L et al. (1991) Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 51:5813-6
Mattern, M R; Nambi, P; Bartus, J O et al. (1991) Regulation of topoisomerase I and II activities by cyclic nucleotide- and phospholipid-dependent protein kinases. Effects of interactions between the two transduction pathways. Receptor 1:181-90
Woessner, R D; Mattern, M R; Mirabelli, C K et al. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-14
Kingsbury, W D; Boehm, J C; Jakas, D R et al. (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107
Woessner, R D; Chung, T D; Hofmann, G A et al. (1990) Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res 50:2901-8
Hertzberg, R P; Busby, R W; Caranfa, M J et al. (1990) Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem 265:19287-95
Hofmann, G A; Mirabelli, C K; Drake, F H (1990) Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II. Anticancer Drug Des 5:273-82

Showing the most recent 10 out of 41 publications